VERACYTE INC
VCYTNASDAQ🏆 #1448 by market capEarnings Nov 4 · PostUS Equity
$51.83▲ $1.52 (+3.03%)
Latest quoteTrack VCYT
Get earnings, price moves & breaking news on Telegram
24h▲ 3.0%
7d▲ 12.5%
14d▲ 16.8%
30d▲ 12.5%
ytd▲ 23.1%
1y▲ 46.3%
🏦Market Cap
$4.17B
Small Cap
📈Revenue Growth (YoY)
17.3%
Healthy
📊Gross Margin
71.7%
High
💵FCF Margin
29.5%
Strong
⚖️P/S Ratio
7.2x
Fair
Otter Score
80
Strong
Trading Snapshot
- Day Range
- $49.80 – $51.87
- 52-Week Range
- $29.46 – $60.91
- Volume (shares)
- 41,131
- Avg Volume (shares)
- —
- Shares Outstanding
- 80.4M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- 35.2
- P/S Ratio
- 7.2x
- EPS (TTM)
- $1.40
- Dividend Yield
- —
- Dilution (1yr)
- +1.9%
VERACYTE INC
VCYTFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$517M▲ +16.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
69.6%▲ +4.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$74M▲ +359.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$127M▲ +98.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
81.4M▲ +1.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$323M▲ +$135M YoY
StockOtter · stockotter.spaceAbout VERACYTE INC
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100
Analyst Ratings
ⓘConsensus
Buy
19 analysts
Strong Buy8
Buy8
Hold2
Sell1
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.